Use of a recurrence score in second breast cancers. (2016)

• Record Type: Journal Article
• Authors: Vera, Nora; Carr, Danielle N.; Mullinax, John; Sun, Weihong; Hoover, Susan; Fulp, William; Acs, Geza; Laronga, Christine; Lee, M. Catherine
• Is Part Of: Cancer treatment and research communications. Number 9(2016)
• Page Start: 1
• Page End: 4
• Publication Date: 2016
• Subjects: Breast cancer -- Recurrence -- Chemotherapy -- Oncotype DX -- Gene assay
• DOI: 10.1016/j.ctarc.2016.06.004
• Languages: English
• ISSNs: 2468-2942

Abstract

Abstract: Introduction: Systemic treatment for second estrogen receptor positive (ER+) invasive breast cancer is controversial. The Recurrence Score (RS) from the 21-gene breast cancer assay (ODX) is used for adjuvant therapy recommendations in primary, early-stage ER+ disease, but has unknown utility in locally recurrent tumors. Methods: An IRB-approved, single-institution retrospective chart review of a prospective ODX database of was performed. Most patients had ODX performed on an initial invasive breast cancer (1° Cancer); a minority had ODX performed on an ipsilateral local recurrence (2nd Cancer); none had clinical evidence of concurrent regional or distant metastasis at presentation. Eligibility for the ODX assay was based on NCCN guidelines (1° breast cancer) or physician discretion (2nd cancer). Data collected included demographics, clinical-pathologic variables, surgery type, RS, adjuvant treatment and outcomes. Comparisons between 1° breast cancer and 2nd were made by general linear regression model and the exact Wilcoxon Rank Sum Test. Results: 594 Patients with 1° breast cancer and 7 patients with 2nd breast cancer had ODX and RS. Median invasive tumor size of both 1° cancer and 2nd cancer was 1.5 (range 0.6–2.0 cm). All 1° and 2nd breast cancers were ER+. Median RS was higher in patients with 2nd cancer [25; range 15–40] compared to 1° cancer [16; range 0–63]( p =0.0084). Categorically, more 2nd cancer patients had a high RS (37.5%) than those with 1° cancer (8.1%) ( p =0.0136). Conclusion: Performance of ODX in ER+, locally recurrent breast cancer (2nd breast cancer) should be considered for prognostication and adjuvant systemic treatment recommendations